05:59 AM EST, 11/03/2026 (MT Newswires) -- Alzinova (ALZ.ST) applied to the US Institutional Review Board Advarra for ethical review and approval of its planned phase 2a Advance study of vaccine candidate ALZ-101 in patients with early Alzheimer's disease. The Swedish biopharmaceutical company said Tuesday that the submission covers seven selected US clinical trial sites, with first patient enrollment expected at the end of 2026 or the beginning of 2027.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.